目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Treatment
1.1.2. End Use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database.
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Outlook
2.2.2. End Use Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights

Chapter 3. Breast Adenocarcinoma Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Prevalence of Breast Cancer
3.2.1.2. Advancements In Treatment Modalities
3.2.2. Market Restraint Analysis
3.2.2.1. Stringent Regulation And Approvals
3.2.2.2. High Cost of Treatments
3.3. Breast Adenocarcinoma Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. COVID-19 Impact

Chapter 4. Global Breast Adenocarcinoma Treatment Market: Treatment Estimates & Trend Analysis
4.1. Global Breast Adenocarcinoma Treatment Market: Treatment Dashboard
4.2. Global Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
4.3. Global Breast Adenocarcinoma Treatment Market, Treatment
4.4. Chemotherapy
4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
4.5. Targeted Therapy
4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
4.6. Hormonal Therapy
4.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
4.7. Immunotherapy
4.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
4.8. Radiation Therapy
4.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)
4.9. Other
4.9.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Breast Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis
5.1. Global Breast Adenocarcinoma Treatment Market: End Use Dashboard
5.2. Global Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
5.3. Global Breast Adenocarcinoma Treatment Market, End Use
5.4. Hospitals
5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.5. Specialty Clinics
5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.6. Others
5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Breast Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and B End Use.
6.1. Regional Market Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.6. Singapore
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape
7.1. Recent Developments and Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company heat map analysis, 2023
7.4. Company Profiles
7.4.1. Merck & Co
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Bristol Myers Squiib
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Kyowa Kirin
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Eisai Co.Ltd
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Sanofi
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Pfizer Inc
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. AstraZeneca
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Novartis AG
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Eli Lilly and Company
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. F. Hoffmann La Roche AG
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 North America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
Table 3 North America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 4 North America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 5 U.S. Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 6 U.S. Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 7 Canada Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 8 Canada Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 9 Europe Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
Table 10 Europe Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 11 Europe Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 12 Germany Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 13 Germany Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 14 UK Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 15 UK Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 16 France Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 17 France Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 18 Italy Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 19 Italy Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 20 Spain Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 21 Spain Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 22 Denmark Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 23 Denmark Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 24 Sweden Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 25 Sweden Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 26 Norway Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 27 Norway Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 28 Asia Pacific Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
Table 29 Asia Pacific Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 30 Asia Pacific Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 31 China Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 32 China Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 33 Japan Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 34 Japan Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 35 India Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 36 India Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 37 South Korea Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 38 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 39 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 40 Australia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 41 Australia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 42 Thailand Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 43 Thailand Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 44 Latin America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
Table 45 Latin America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 46 Latin America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 47 Brazil Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 48 Brazil Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 49 Mexico Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 50 Mexico Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 51 Argentina Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 52 Argentina Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 53 MEA Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
Table 54 MEA Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 55 MEA Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 56 South Africa Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 57 South Africa Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 58 Saudi Arabia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 59 Saudi Arabia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 60 UAE Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 61 UAE Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
Table 62 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 63 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 64 Kuwait Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Breast Adenocarcinoma Treatment Market: Market Outlook
Fig. 9 Breast Adenocarcinoma Treatment Competitive Insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Breast Adenocarcinoma Treatment Market Driver Impact
Fig. 15 Breast Adenocarcinoma Treatment Market Restraint Impact
Fig. 16 Breast Adenocarcinoma Treatment Market Strategic Initiatives Analysis
Fig. 17 Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
Fig. 18 Breast Adenocarcinoma Treatment Market: Treatment Outlook And Key Takeaways
Fig. 19 Chemotherapy market estimates and forecast, 2018 - 2030
Fig. 20 Targeted therapy market estimates and forecast, 2018 - 2030
Fig. 21 Hormonal therapy market estimates and forecast, 2018 - 2030
Fig. 22 Immunotherapy market estimates and forecast, 2018 - 2030
Fig. 23 Radiation therapy market estimates and forecast, 2018 - 2030
Fig. 24 Other market estimates and forecast, 2018 - 2030
Fig. 25 Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
Fig. 26 Breast Adenocarcinoma Treatment Market: End Use Outlook And Key Takeaways
Fig. 27 Hospitals market estimates and forecast, 2018 - 2030
Fig. 28 Specialty clinics market estimates and forecast, 2018 - 2030
Fig. 29 Global Breast Adenocarcinoma Treatment Market: Regional Movement Analysis
Fig. 30 Global Breast Adenocarcinoma Treatment Market: Regional Outlook And Key Takeaways
Fig. 31 Global Breast Adenocarcinoma Treatment market share and leading companies
Fig. 32 North America: SWOT
Fig. 33 Europe SWOT
Fig. 34 Asia Pacific SWOT
Fig. 35 Latin America SWOT
Fig. 36 MEA SWOT
Fig. 37 North America, by country
Fig. 38 North America
Fig. 39 North America market estimates and forecasts, 2018 - 2030
Fig. 40 U.S.
Fig. 41 U.S. market estimates and forecasts, 2018 - 2030
Fig. 42 Canada
Fig. 43 Canada market estimates and forecasts, 2018 - 2030
Fig. 44 Mexico
Fig. 45 Mexico market estimates and forecasts, 2018 - 2030
Fig. 46 Europe
Fig. 47 Europe market estimates and forecasts, 2018 - 2030
Fig. 48 UK
Fig. 49 UK market estimates and forecasts, 2018 - 2030
Fig. 50 Germany
Fig. 51 Germany market estimates and forecasts, 2018 - 2030
Fig. 52 France
Fig. 53 France market estimates and forecasts, 2018 - 2030
Fig. 54 Italy
Fig. 55 Italy market estimates and forecasts, 2018 - 2030
Fig. 56 Spain
Fig. 57 Spain market estimates and forecasts, 2018 - 2030
Fig. 58 Denmark
Fig. 59 Denmark market estimates and forecasts, 2018 - 2030
Fig. 60 Sweden
Fig. 61 Sweden market estimates and forecasts, 2018 - 2030
Fig. 62 Norway
Fig. 63 Norway market estimates and forecasts, 2018 - 2030
Fig. 64 Asia Pacific
Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 66 China
Fig. 67 China market estimates and forecasts, 2018 - 2030
Fig. 68 Japan
Fig. 69 Japan market estimates and forecasts, 2018 - 2030
Fig. 70 India
Fig. 71 India market estimates and forecasts, 2018 - 2030
Fig. 72 Singapore
Fig. 73 Singapore market estimates and forecasts, 2018 - 2030
Fig. 74 South Korea
Fig. 75 South Korea market estimates and forecasts, 2018 - 2030
Fig. 76 Australia
Fig. 77 Australia market estimates and forecasts, 2018 - 2030
Fig. 78 Latin America
Fig. 79 Latin America market estimates and forecasts, 2018 - 2030
Fig. 80 Brazil
Fig. 81 Brazil market estimates and forecasts, 2018 - 2030
Fig. 82 Argentina
Fig. 83 Argentina market estimates and forecasts, 2018 - 2030
Fig. 84 Middle East and Africa
Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 86 South Africa
Fig. 87 South Africa market estimates and forecasts, 2018 - 2030
Fig. 88 Saudi Arabia
Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 90 UAE
Fig. 91 UAE market estimates and forecasts, 2018 - 2030
Fig. 92 Kuwait
Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 94 Market share of key market companies - Breast Adenocarcinoma Treatment market